A Comprehensive Monograph on Deflazacort (DB11921): Pharmacology, Clinical Efficacy, and Regulatory Landscape

Executive Summary

Deflazacort is a synthetic oxazoline derivative of prednisolone, classified as a corticosteroid prodrug. Following oral administration, it is rapidly converted to its active metabolite, 21-desacetyldeflazacort, which functions as a potent glucocorticoid receptor agonist, exerting broad anti-inflammatory and immunosuppressive effects.[1] In the United States, its sole approved indication is the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged two years and older, a rare, progressive, and fatal genetic disorder characterized by muscle degeneration.[1] Clinical evidence has firmly established its efficacy in slowing the decline of muscle strength and function, delaying the loss of ambulation, preserving cardiorespiratory capacity, and reducing the incidence of scoliosis in this patient population.[1]

Despite its clinical benefits, the therapeutic profile of deflazacort is defined by a complex series of trade-offs, particularly when compared to prednisone, another corticosteroid widely used off-label for DMD. Deflazacort is associated with a more favorable profile regarding weight gain and behavioral disturbances. Conversely, it may present a higher risk of adverse effects on bone mineral density, growth velocity in children, and cataract formation.[3] This nuanced safety profile necessitates careful, individualized clinical decision-making.

The drug's regulatory and commercial history in the United States is particularly noteworthy. Although patented in 1969 and used for decades in other countries for various inflammatory conditions, it was navigated through the U.S. Food and Drug Administration (FDA) orphan drug pathway, receiving approval for DMD in 2017.[6] The subsequent announcement of a high list price generated significant controversy, positioning deflazacort as a prominent case study in the debate surrounding orphan drug incentives, drug repositioning, and pharmaceutical pricing ethics. The recent introduction of generic versions in the U.S. is expected to significantly alter its accessibility and place in therapy.[2]

Drug Identification and Physicochemical Properties

Precise identification of a pharmaceutical agent is fundamental for research, clinical practice, and regulatory affairs. Deflazacort is a well-characterized small molecule with numerous identifiers across global databases and markets.

Nomenclature and Identifiers

Deflazacort is known by a variety of chemical names, synonyms, and brand names worldwide. Its systematic IUPAC name isicosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate.[9] A common chemical synonym is 11β,21-dihydroxy-2'-methyl-5'βH-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate.[1]

In the United States, it is marketed under the brand names Emflaza, Jaythari, and Pyquvi.[1] Internationally, it has been available for many years under various trade names, including Calcort in the United Kingdom; Cortax, Decortil, Defcort, and Deflanil in Brazil; Moaid, Zenflav, and DefZot in India; Xalcort in Bangladesh; Zamen in Panama and Spain; and Flezacor in Honduras.[6] Table 1 provides a consolidated list of its key identifiers.

Table 1: Drug Identification and Key Database Identifiers

Identifier Type	Identifier Value	Source/Database
DrugBank ID	DB11921	DrugBank 9
CAS Number	14484-47-0	CAS Common Chemistry 9
UNII	KR5YZ6AE4B	FDA Global Substance Registration System (GSRS) 9
Chemical Formula	C${25}H{31}NO_{6}$	PubChem 9
ATC Code	H02AB13	Drugs.com 10
EC Number	238-483-7	European Chemicals Agency (ECHA) 9
ChEBI ID	CHEBI:135720	Chemical Entities of Biological Interest 9
ChEMBL ID	CHEMBL1201891	ChEMBL 9
KEGG ID	D03671	Kyoto Encyclopedia of Genes and Genomes 9
RxCUI	22396	NLM RxNorm 9
U.S. Brand Name	Emflaza	PTC Therapeutics, Inc. 11
U.K. Brand Name	Calcort	Wikipedia 6

Chemical Structure and Physicochemical Properties

Deflazacort is a synthetic glucocorticoid belonging to the acetonide or O-isopropylidene derivative class.[6] Its chemical formula is

C25​H31​NO6​.[9]

Key computed physicochemical properties influence its behavior in biological systems:

• Molecular Weight: The average molecular weight is 441.5 g/mol.[9]
• Monoisotopic Mass: 441.21513771 Da.[9]
• Topological Polar Surface Area (TPSA): 102 Ų.[9]
• Hydrogen Bond Donor/Acceptor Count: It has 1 hydrogen bond donor and 7 hydrogen bond acceptors.[9]
• Rotatable Bond Count: 4.[9]

These properties, particularly its polarity and hydrogen bonding capacity, are determinants of its absorption, distribution, and ability to interact with its molecular target.

Pharmacology and Mechanism of Action

The pharmacological activity of deflazacort is characteristic of the corticosteroid class, defined by its conversion to an active metabolite that modulates gene expression through the glucocorticoid receptor.

Pharmacodynamics

Deflazacort itself is an inactive prodrug. Following oral administration, it undergoes rapid and extensive first-pass metabolism by plasma esterases, which hydrolyze the 21-acetate group to form the pharmacologically active metabolite, 21-desacetyldeflazacort (also known as 21-desDFZ).[1] This active metabolite is responsible for the drug's systemic effects.

The mechanism of action of 21-desDFZ is as a Corticosteroid Hormone Receptor Agonist.[9] It binds with high affinity to the cytosolic glucocorticoid receptor (GR). This drug-receptor complex then translocates to the nucleus, where it functions as a ligand-dependent transcription factor. The complex can directly bind to specific DNA sequences known as glucocorticoid response elements (GREs) in the promoter regions of target genes, leading to either the transactivation (upregulation) of anti-inflammatory genes or the transrepression (downregulation) of pro-inflammatory genes.[1] This modulation of gene expression results in broad anti-inflammatory and immunosuppressive effects, which form the basis of its therapeutic utility.[2]

While these general mechanisms are well-established for all glucocorticoids, the precise molecular pathway by which deflazacort exerts its specific therapeutic effects in patients with DMD remains unknown.[1] It is hypothesized that by reducing inflammation and suppressing the immune system's activity within dystrophic muscle, deflazacort mitigates the chronic inflammatory cascade that contributes to muscle fiber necrosis and fibrosis, thereby slowing the progressive muscle damage characteristic of the disease.[9]

Pharmacokinetics

The pharmacokinetic profile of deflazacort describes its absorption, distribution, metabolism, and elimination (ADME), which collectively determine the onset, intensity, and duration of its therapeutic action.

Absorption: Deflazacort is rapidly absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations (Cmax​) of the active metabolite, 21-desDFZ, are typically reached within 1 to 2 hours (Tmax​).[1] The bioavailability of the oral tablet and oral suspension formulations is similar. Co-administration with food does not significantly alter the overall systemic absorption (as measured by the area under the curve, AUC), although a high-fat meal may reduce the peak concentration by approximately 30% and delay the time to peak by one hour.[1] For ease of administration, particularly in pediatric patients, the tablets may be crushed and mixed with applesauce without affecting absorption or bioavailability.[3]

Distribution: The active metabolite, 21-desDFZ, is approximately 40% bound to plasma proteins.[1] This is a relatively low degree of protein binding compared to some other corticosteroids, such as prednisolone, which exhibits concentration-dependent binding.[16] The volume of distribution has been determined to be 204 ± 84 L.[1]

Metabolism: As a prodrug, deflazacort's activation is the first metabolic step. The resulting active metabolite, 21-desDFZ, is subsequently metabolized in the liver, primarily by the cytochrome P450 3A4 (CYP3A4) isoenzyme, into several other inactive metabolites, including 6β-hydroxy-21-desacetyl deflazacort.[15] This heavy reliance on the CYP3A4 pathway is the mechanistic basis for deflazacort's most clinically significant drug-drug and drug-food interactions. Any substance that inhibits or induces CYP3A4 activity can profoundly alter the plasma concentrations of 21-desDFZ, necessitating dose adjustments or avoidance of co-administration.

Excretion: The elimination of deflazacort and its metabolites is predominantly via the kidneys, with approximately 68-70% of an administered dose excreted in the urine.[6] The remaining 30% is eliminated through fecal excretion.[6] The elimination process is rapid, with nearly all of the drug cleared within 24 hours post-dose.[15] The elimination half-life (

t1/2​) of the active metabolite is correspondingly short, ranging from 1.1 to 1.9 hours.[6] Pharmacokinetics are not significantly altered by mild to moderate hepatic impairment or by any degree of renal impairment.[15]

Table 2: Summary of Pharmacokinetic Parameters

Parameter	Value / Description	Source(s)
Absorption
Time to Peak (Tmax​)	1–2 hours	1
Bioavailability	Similar for oral tablet and suspension formulations	1
Food Effect	No significant effect on overall absorption (AUC); high-fat meal may reduce Cmax​ by ~30%	1
Distribution
Protein Binding	~40% (for active metabolite 21-desDFZ)	1
Metabolism
Activation Pathway	Prodrug converted to active 21-desDFZ via plasma esterases	1
Primary Metabolic Enzyme	CYP3A4 (for active metabolite 21-desDFZ)	15
Excretion
Primary Route	~70% Renal (urinary)	6
Secondary Route	~30% Fecal	6
Elimination Half-Life (t1/2​)	1.1–1.9 hours (for active metabolite 21-desDFZ)	6

Clinical Applications and Efficacy

While deflazacort possesses broad anti-inflammatory properties applicable to many conditions, its modern clinical identity, particularly in the United States, is defined by its indication for Duchenne muscular dystrophy.

FDA-Approved Indication: Duchenne Muscular Dystrophy (DMD)

DMD is a devastating X-linked genetic disorder caused by mutations in the gene encoding the dystrophin protein. The absence of functional dystrophin destabilizes the muscle fiber membrane, leading to progressive muscle fiber necrosis, chronic inflammation, fibrosis, and eventual replacement of muscle with fat and connective tissue.[9] This pathology manifests as relentless muscle weakness, loss of ambulation in early adolescence, and ultimately, fatal cardiorespiratory failure.[9] The therapeutic rationale for using corticosteroids is to interrupt the cycle of inflammation that exacerbates muscle damage.[3]

The U.S. FDA has approved deflazacort for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older, regardless of the specific genetic mutation.[2] Extensive clinical data support its efficacy in modifying the course of the disease. Key findings from clinical studies include:

• Improvement in Muscle Strength: A pivotal, 52-week, randomized, placebo-controlled trial demonstrated that patients treated with deflazacort (0.9 mg/kg/day) had a statistically significant improvement in average muscle strength compared to placebo at 12 weeks.[19]
• Delayed Disease Progression and Loss of Ambulation: Long-term observational studies and clinical trials have shown that deflazacort delays the onset of muscle-related complications.[1] Compared to no treatment, glucocorticoid therapy has been shown to delay the loss of key mobility milestones by 2.1 to 4.4 years.[19] In one study, the mean age of ambulation loss was extended by approximately two years in the deflazacort-treated group compared to controls.[1]
• Preservation of Cardiorespiratory Function: Chronic treatment with deflazacort has been associated with better preservation of cardiac and respiratory function. Studies have reported a higher mean left ventricular ejection fraction and a slower decline in functional respiratory parameters in treated patients compared to untreated cohorts.[1]
• Reduction in Orthopedic Complications: Deflazacort therapy significantly reduces the incidence and severity of scoliosis (curvature of the spine), a common complication in DMD. In some long-term studies, the need for corrective spinal surgery was eliminated in the treated group.[1]

Historical and Off-Label Uses

Deflazacort's approval for DMD in the U.S. in 2017 represents a relatively recent chapter in its long history. The drug was first patented in 1969 and received its initial approvals for medical use in 1985.[6] For decades prior to its U.S. launch, it was widely used in Europe and other parts of the world as a first-line or alternative corticosteroid for a range of inflammatory and autoimmune diseases. These historical and ongoing off-label uses include:

• Rheumatoid arthritis
• Juvenile chronic arthritis
• Systemic lupus erythematosus (SLE)
• Nephrotic syndrome
• Asthma
• Polymyalgia rheumatica
• Sarcoidosis
• Various dermatological conditions like bullous pemphigoid.[6]

Before it was formally approved by the FDA, many patients with DMD in the U.S. obtained deflazacort from international sources under personal importation policies, reflecting its long-standing recognition as a standard of care by the global neuromuscular community.[7]

The FDA's designation of deflazacort as a "first-in-class" medication for DMD is a regulatory classification that merits careful interpretation.[6] This terminology does not imply that deflazacort is a novel chemical entity or that it possesses a unique mechanism of action; it is a member of the well-established corticosteroid class. Instead, the designation signifies that it was the first drug of any kind to successfully complete the formal regulatory process and receive specific FDA approval for the DMD indication. This distinction is crucial, as it highlights how the U.S. regulatory framework, particularly the orphan drug pathway, can re-contextualize a long-established, multi-indication compound as "new" and "innovative" for a specific, underserved patient population. This re-contextualization was a key factor that enabled the market exclusivity and pricing strategy that characterized its U.S. launch.

Regulatory and Commercial History

The story of deflazacort in the United States is a complex interplay of regulatory strategy, pharmaceutical economics, and patient advocacy, serving as a significant case study in modern drug development.

United States (FDA) Approval Pathway

The journey of deflazacort to the U.S. market was strategically managed to leverage regulatory incentives designed for rare diseases.

• Orphan Drug Designation: On August 16, 2013, the FDA granted deflazacort an orphan designation for the treatment of DMD, a critical first step that provides benefits such as market exclusivity and tax credits.[27]
• Fast Track Designation: In January 2015, Marathon Pharmaceuticals, the sponsor at the time, received Fast Track designation from the FDA. This status is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.[28]
• Initial Approval: Following the submission of its New Drug Application (NDA), deflazacort, under the brand name Emflaza, was granted FDA approval on February 9, 2017. The initial indication was for the treatment of DMD in patients aged 5 years and older.[3] It was approved as a Type 1 New Molecular Entity with orphan status, which conferred seven years of market exclusivity.[6]
• Label Expansion: The therapeutic reach of Emflaza was broadened on June 7, 2019, when the FDA approved a label expansion to include the treatment of younger patients, from 2 to 5 years of age. This expansion came with its own period of market exclusivity for the new pediatric population, extending until June 7, 2026.[8]

European (EMA) and International Status

In stark contrast to its highly regulated and recent entry into the U.S. market, deflazacort has been an established part of the therapeutic armamentarium in Europe and other regions for decades. It has been prescribed off-label for DMD for many years, based on clinical experience and academic research.[7] The provided documentation does not indicate that deflazacort holds a formal, centralized marketing authorization from the European Medicines Agency (EMA) specifically for the DMD indication. The recent EMA recommendation for approval of vamorolone as the "first ever treatment for all patients with Duchenne" further supports the conclusion that deflazacort does not hold this specific, pan-European approval for DMD.[29] In many countries, including Canada and the United Kingdom, it has long been available as an inexpensive generic medication.[6]

Economic and Societal Context: The Pricing Controversy

The U.S. launch of deflazacort became a flashpoint in the national debate on drug pricing. The situation exemplifies the "orphan drug paradox," where incentives designed to foster innovation for rare diseases are applied to pre-existing, low-cost drugs. Marathon Pharmaceuticals executed a strategy of acquiring the rights to deflazacort, a compound with decades of real-world safety and efficacy data, and navigating it through the U.S. orphan drug pathway. This process minimized research and development risk while maximizing the commercial reward of market exclusivity.[7]

Upon receiving FDA approval, Marathon announced a list price of $89,000 per year for Emflaza. This represented an approximately 60-fold increase over the cost for patients who had been importing the drug from the U.K. or Canada, where it was available for around $1 per tablet.[6] The announcement triggered a swift and severe backlash from patient advocacy groups, physicians, and U.S. legislators, who accused the company of "price-gouging" and unethically exploiting a vulnerable patient population and the regulatory system.[6]

The intense public and political pressure led Marathon to "pause" its launch. Shortly thereafter, in March-April 2017, the company sold all rights to Emflaza to PTC Therapeutics for $140 million plus sales-based milestones.[6] PTC Therapeutics then proceeded with the commercial launch.

This episode created a significant tension between two competing public interests: enabling U.S. patients to access an effective, FDA-vetted therapy through standard prescription channels, and protecting the healthcare system and patients from what was widely perceived as predatory pricing behavior.[7] The market exclusivity granted by the orphan drug status expired for the initial indication on February 9, 2024.[27] This opened the door for generic competition, which materialized quickly. In early 2024, Aurobindo Pharma received approval for generic deflazacort tablets, and in June 2024, Cranbury Pharmaceuticals (a subsidiary of Tris Pharma) gained approval for the first generic oral suspension.[2] The entry of these lower-cost generics is expected to dramatically increase the accessibility of deflazacort for DMD patients in the U.S. and fundamentally alter the economic landscape of its use.

Dosage, Administration, and Formulations

Proper dosing and administration are critical to maximizing the efficacy and minimizing the risks of deflazacort therapy.

Available Formulations

Deflazacort is commercially available in the U.S. under the brand name Emflaza in two oral formulations to accommodate patient needs, particularly in the pediatric population [18]:

• Tablets: Immediate-release tablets are available in four strengths: 6 mg, 18 mg, 30 mg, and 36 mg. The tablets are differentiated by size, shape, and debossing:
• 6 mg: White, round, with "6" debossed on one side.
• 18 mg: White, round, with "18" debossed on one side.
• 30 mg: White, oval, with "30" debossed on one side.
• 36 mg: White, oval, with "36" debossed on one side.[30]
• Oral Suspension: A whitish-colored liquid formulation is available at a concentration of 22.75 mg/mL.[30]

Recommended Dosing Regimen

The dosing of deflazacort for DMD is based on patient body weight.

• Standard Dosage: The recommended once-daily oral dosage for patients with DMD (aged 2 years and older) is approximately 0.9 mg/kg/day.[18]
• Dose Calculation and Rounding: Because the available formulations come in fixed strengths, the calculated dose must be rounded. For patients taking tablets, the dose should be rounded up to the nearest possible dose, which can be achieved by using any combination of the available tablet strengths. For patients using the oral suspension, the dose should be rounded up to the nearest tenth of a milliliter (mL).[30]
• Dose Optimization Research: While 0.9 mg/kg/day is the FDA-recommended dose, research into dose optimization is ongoing. One randomized, non-inferiority trial compared this standard dose to a lower dose of 0.45 mg/kg/day. The study found that the standard dose was more effective overall. However, it also suggested that the lower dose might be non-inferior for a specific subgroup of younger patients (≤7 years of age) with better baseline function (a six-minute walk distance >350 meters) and was associated with a lower incidence of adverse events. This finding points toward the potential for more individualized, risk-stratified dosing strategies in the future.[34]

Administration Instructions

To ensure proper delivery and absorption, specific administration instructions should be followed.

• General: Deflazacort can be taken once daily, with or without food, at approximately the same time each day.[35]
• Tablets: Tablets may be swallowed whole. For patients who have difficulty swallowing, the tablets can be crushed and mixed with applesauce. The mixture must be consumed immediately after preparation.[3]
• Oral Suspension: The bottle of oral suspension must be shaken well before each use. The dose must be measured using only the calibrated oral dispenser provided with the product. The measured dose should then be slowly added to 3 to 4 ounces of juice (excluding grapefruit juice) or milk, mixed well, and administered immediately. The oral dispenser should be cleaned after each use. Any unused suspension must be discarded one month after the bottle is first opened.[30]
• Grapefruit Juice Prohibition: A critical administration instruction is the strict avoidance of grapefruit and grapefruit juice, as it is a potent inhibitor of the CYP3A4 enzyme responsible for metabolizing deflazacort, which can lead to dangerously elevated drug levels.[30]

Discontinuation Protocol

As with all systemic corticosteroids administered for more than a few days, deflazacort must not be stopped abruptly. Doing so can precipitate acute adrenal insufficiency, a potentially fatal condition resulting from the suppression of the hypothalamic-pituitary-adrenal (HPA) axis. To prevent this, the dosage must be decreased gradually under medical supervision. Abrupt withdrawal can also trigger a steroid withdrawal syndrome, characterized by symptoms such as anorexia, nausea, fever, myalgia, and lethargy.[30]

Comprehensive Safety Profile

The use of deflazacort, like all corticosteroids, is associated with a wide range of potential adverse effects and requires careful patient monitoring and risk management.

Contraindications

The only absolute contraindication listed for deflazacort is a known hypersensitivity to the drug substance or any of the inactive ingredients in the formulation. Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy.[40]

Warnings and Precautions

The long-term use of deflazacort carries significant risks that affect multiple organ systems. These are class-wide effects for corticosteroids.

• Endocrine Alterations: Chronic use can lead to serious and life-threatening endocrine dysfunction. This includes reversible HPA axis suppression, which can lead to secondary adrenal insufficiency upon withdrawal; iatrogenic Cushing's syndrome from prolonged exposure to high levels of the drug; and hyperglycemia, which can worsen pre-existing diabetes or precipitate new-onset diabetes mellitus.[1] Patients with pre-existing thyroid disorders may require dose adjustments due to altered corticosteroid metabolism.[18] Fatal pheochromocytoma crisis has also been reported after systemic corticosteroid administration.[41]
• Immunosuppression and Increased Risk of Infection: Deflazacort suppresses the immune system, increasing susceptibility to infections of all types (bacterial, viral, fungal, protozoan) and increasing the risk that these infections will be more severe or fatal. It can also mask the signs and symptoms of an ongoing infection. Patients should be warned to avoid exposure to individuals with chickenpox or measles. Reactivation of latent infections, such as tuberculosis or hepatitis B, is a significant concern.[5]
• Cardiovascular and Renal Effects: Corticosteroids can cause elevations in blood pressure, salt and water retention, and increased potassium excretion. This necessitates caution in patients with hypertension, congestive heart failure, or renal insufficiency.[40]
• Gastrointestinal Perforation: There is an increased risk of gastrointestinal perforation, particularly in patients with underlying conditions such as peptic ulcer disease, diverticulitis, or inflammatory bowel disease. The anti-inflammatory effects of the drug may mask the typical signs of an acute abdomen.[40]
• Behavioral and Mood Disturbances: A range of psychiatric adverse reactions can occur, including euphoria, insomnia, mood swings, personality changes, severe depression, and frank psychosis. Patients and caregivers should be counseled to report any significant changes in mood or behavior.[40]
• Effects on Bones: Long-term corticosteroid use is a well-known cause of decreased bone mineral density by inhibiting osteoblast function and increasing osteoclast activity. This leads to osteoporosis and an increased risk of vertebral and long bone fractures.[6]
• Ophthalmic Effects: Chronic use can lead to the formation of posterior subcapsular cataracts and may cause glaucoma with potential damage to the optic nerve. Regular ophthalmic examinations are recommended for patients on long-term therapy.[11]
• Vaccination: Patients receiving immunosuppressive doses of deflazacort should not be administered live or live-attenuated vaccines. It is recommended that all necessary immunizations be completed at least 4 to 6 weeks prior to initiating therapy.[40]
• Other Serious Risks: Other reported serious risks include the development of an acute myopathy (particularly when used with neuromuscular blocking agents), the emergence of Kaposi's sarcoma, an increased risk of thromboembolic events, and rare but severe skin reactions such as toxic epidermal necrolysis (TEN).[40]

Adverse Reactions

The most common adverse reactions are consistent with the known side effect profile of glucocorticoids. Data from the pivotal 12-week, placebo-controlled study in DMD provides a quantitative assessment of these risks.

Table 3: Common Adverse Reactions in DMD Clinical Trials (Deflazacort 0.9 mg/kg/d vs. Placebo at 12 Weeks) [15]

Adverse Reaction	Deflazacort 0.9 mg/kg/d (N=51) %	Placebo (N=50) %
Cushingoid appearance	33	12
Weight increased	20	6
Increased appetite	14	2
Upper respiratory tract infection	12	10
Cough	12	6
Pollakiuria (Frequent daytime urination)	12	2
Nasopharyngitis	10	6
Hirsutism (Unwanted hair growth)	10	2
Central obesity	10	4
Erythema	8	6
Irritability	8	4
Rhinorrhea	8	0
Abdominal discomfort	6	2

Drug and Food Interactions

The clinical use of deflazacort must account for its significant potential for interactions, which are primarily driven by its metabolism via the CYP3A4 enzyme system.

• CYP3A4 Inhibitors: Co-administration of deflazacort with moderate or strong inhibitors of CYP3A4 will significantly increase the plasma concentration and exposure of the active metabolite, 21-desDFZ, thereby increasing the risk of adverse effects. When this combination is necessary, the deflazacort dosage must be reduced to one-third of the recommended dose. Examples of interacting inhibitors include clarithromycin, fluconazole, diltiazem, verapamil, and grapefruit juice.[18]
• CYP3A4 Inducers: Conversely, co-administration with moderate or strong inducers of CYP3A4 will accelerate the metabolism of 21-desDFZ, leading to substantially lower plasma concentrations and a potential loss of therapeutic efficacy. Therefore, the concomitant use of deflazacort with these agents should be avoided. Examples of interacting inducers include rifampin, carbamazepine, phenytoin, efavirenz, and the herbal supplement St. John's Wort.[9]
• Food Interactions: The only significant food interaction is with grapefruit and grapefruit juice. Due to its potent CYP3A4 inhibitory effects, consumption of grapefruit products must be avoided during deflazacort therapy.[9]
• Other Drug Interactions: Deflazacort may interact with numerous other medications. Co-administration with NSAIDs can increase the risk of gastrointestinal irritation and ulceration. Its potential to cause hypokalemia can be exacerbated when used with other potassium-depleting drugs like certain diuretics or amphotericin B. It may also increase the anticoagulant activities of drugs like acenocoumarol.[1]

Comparative Analysis: Deflazacort vs. Prednisone/Prednisolone

In the management of DMD, both deflazacort and prednisone/prednisolone are considered standards of care, making a direct comparison essential for clinical decision-making.[26] The choice between them is not straightforward and involves balancing nuanced differences in efficacy, potency, and, most importantly, their distinct side effect profiles.

Pharmacological and Potency Comparison

Deflazacort is an oxazoline derivative of prednisolone, a structural modification that confers some of its unique pharmacological properties.[12] While both are potent anti-inflammatory agents, they are not equipotent on a milligram-for-milligram basis. The generally accepted dosing equivalence is that

6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisone or prednisolone, a ratio of 1.2:1.[6] This difference in potency is reflected in the recommended daily dosages for DMD: approximately 0.9 mg/kg for deflazacort versus 0.75 mg/kg for prednisone.[32]

A key pharmacological differentiator is their effect on mineralocorticoid receptors. Deflazacort and its active metabolite have little to no affinity for these receptors, which are responsible for sodium and water retention. In contrast, prednisone possesses significant mineralocorticoid activity. This difference likely explains deflazacort's lower propensity to cause fluid retention and hypertension.[16]

Comparative Efficacy in DMD

Both deflazacort and prednisone have been proven to be superior to placebo in improving muscle strength and slowing disease progression in DMD. When compared directly against each other, the evidence suggests potential advantages for deflazacort in long-term functional outcomes.

• Short-Term Efficacy: In the initial 12 weeks of treatment, studies have shown that both drugs provide a similar, significant improvement in muscle strength compared to placebo, with no clear superiority of one over the other in this early phase.[20]
• Long-Term Efficacy: Evidence from longer-term studies and meta-analyses of clinical trial data suggests a divergence in outcomes. Several analyses have found that patients treated with deflazacort experience a slower rate of functional decline over 48-52 weeks. One pivotal study reported that from week 12 to week 52, muscle strength continued to improve in the deflazacort group while it worsened in the prednisone group.[20] Post-hoc analyses have shown that deflazacort is associated with better preservation of the 6-minute walk distance and other timed function tests compared to prednisone over a 48-week period.[51] These findings suggest that deflazacort may offer a greater cumulative benefit in preserving ambulatory function over time.

Comparative Safety and Tolerability

The most significant differences between the two drugs lie in their side effect profiles. The clinical choice often hinges on which set of potential adverse effects is considered more manageable or less detrimental for an individual patient.

• Weight Gain: This is one of the most consistent and clinically relevant differences. Multiple studies have demonstrated that deflazacort is associated with significantly less weight gain than prednisone.[4] This can be a major advantage in managing the overall health and quality of life of patients with DMD.
• Behavioral Effects: Deflazacort is generally reported to have a more favorable behavioral profile, with a lower incidence of adverse effects like irritability, aggression, and mood swings compared to prednisone.[5] This difference may be attributable to deflazacort's lower lipid solubility, which results in poorer penetration across the blood-brain barrier.[16]
• Bone Health and Growth: The comparative impact on bone and growth is complex. While some earlier and non-DMD-specific studies suggested deflazacort had a better bone safety profile, more recent data from DMD cohorts indicate that deflazacort may be associated with more pronounced growth suppression and a higher risk of vertebral fractures than prednisone.[4]
• Cataracts: Deflazacort is associated with a higher risk of developing asymptomatic posterior subcapsular cataracts compared to prednisone.[4]

The decision between deflazacort and prednisone is therefore not a matter of selecting a superior drug, but rather a process of individualized risk-benefit assessment. It represents a clinical trade-off: one must weigh the benefits of reduced weight gain and fewer behavioral issues with deflazacort against its higher risk of cataracts and potentially greater negative impact on bone and growth. This decision must be made in consultation with the patient and their family, taking into account their specific clinical status, risk factors, and tolerance for different side effect profiles. Historically, the substantially higher cost of brand-name deflazacort in the U.S. was a significant non-clinical barrier, although the recent availability of generics may mitigate this factor.

Table 4: Comparative Profile of Deflazacort vs. Prednisone in DMD

Feature	Deflazacort	Prednisone / Prednisolone
Dosing Equivalence	~6 mg deflazacort ≈ 5 mg prednisone (1.2:1 ratio)	Standard comparator
Recommended DMD Dose	~0.9 mg/kg/day	~0.75 mg/kg/day
Efficacy (Muscle Strength)	Effective; may offer greater benefit in preserving strength over the long term (>12 weeks)	Effective; standard of care
Efficacy (Ambulation)	May be superior in delaying loss of ambulation and slowing decline in timed function tests	Effective at delaying loss of ambulation vs. no treatment
Side Effect: Weight Gain	Significantly less pronounced	More pronounced; a common and significant issue
Side Effect: Behavioral Issues	Fewer issues reported (e.g., irritability, aggression)	More issues reported
Side Effect: Bone Health/Growth	Associated with greater growth suppression and potentially higher fracture risk in DMD cohorts	May have a less detrimental impact on bone and growth
Side Effect: Cataracts	Higher risk of asymptomatic cataract formation	Lower risk
Mineralocorticoid Activity	Minimal to none	Present; can contribute to fluid retention
U.S. Cost (Historical)	Very high (brand name)	Low (generic)
U.S. Cost (Current)	High (brand name); lower-cost generics now available	Low (generic)

Conclusion and Future Directions

Deflazacort is a well-established corticosteroid that has been repositioned as a primary, FDA-approved therapy for Duchenne muscular dystrophy. Its efficacy in slowing the relentless progression of this disease is well-documented, offering tangible benefits in preserving muscle strength, prolonging ambulation, and protecting cardiorespiratory function. Its primary clinical advantage over the traditional standard of care, prednisone, lies in its demonstrably better profile concerning weight gain and behavioral side effects—two issues that significantly impact the quality of life for patients and their families.

However, these benefits are counterbalanced by a distinct set of risks, including a higher incidence of cataracts and potentially more severe effects on linear growth and bone health. This complex safety profile underscores that there is no universally superior corticosteroid for all patients with DMD. The therapeutic choice must be a highly individualized one, carefully weighing the specific risks and benefits for each patient.

The commercial history of deflazacort in the United States serves as a powerful and cautionary tale in pharmaceutical economics, highlighting the tensions between the laudable goals of the Orphan Drug Act and the potential for market strategies that lead to exorbitant pricing for established medicines. The recent introduction of generic alternatives marks a pivotal shift, promising to improve access and potentially rebalance the clinical decision-making process by reducing the influence of cost.

Looking forward, the role of deflazacort will continue to be defined within an evolving therapeutic landscape for DMD. The advent of novel therapies, including next-generation steroids like vamorolone, which are designed to uncouple anti-inflammatory efficacy from classic steroid side effects, as well as an expanding array of mutation-specific genetic therapies, will likely lead to more complex, combination-based treatment paradigms.[17] Future research will be essential to determine the optimal use of deflazacort—whether as a foundational monotherapy for certain patient subgroups or as a component of a multi-drug regimen—in the ongoing effort to transform the future for all individuals living with Duchenne muscular dystrophy.

Works cited

1. Deflazacort: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 9, 2025, https://go.drugbank.com/drugs/DB11921
2. EMFLAZA® - Parent Project Muscular Dystrophy, accessed September 9, 2025, https://www.parentprojectmd.org/drug-development-pipeline/emflaza/
3. Emflaza (Deflazacort) - Powell Center for Rare Disease Research and Therapy, accessed September 9, 2025, https://raredisease.powellcenter.med.ufl.edu/pediatric-care-center/fda-approved-treatments-faq/emflaza-deflazacort/
4. A review of the literature compares prednisone and deflazacort in DMD and favours the latter in the short term, while in the long term their effects are similar, accessed September 9, 2025, https://www.institut-myologie.org/en/2022/09/22/a-review-of-the-literature-compares-prednisone-and-deflazacort-in-dmd-and-favours-the-latter-in-the-short-term-while-in-the-long-term-their-effects-are-similar/
5. Safety & Side Effects - EMFLAZA® (deflazacort), accessed September 9, 2025, https://www.emflaza.com/safety
6. Deflazacort - Wikipedia, accessed September 9, 2025, https://en.wikipedia.org/wiki/Deflazacort
7. How to prevent the next Marathon Pharmaceuticals - PMC - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5865197/
8. The FDA Greenlights Generic Deflazacort for the Treatment of Duchenne Muscular Dystrophy - - PracticalNeurology, accessed September 9, 2025, https://practicalneurology.com/news/the-fda-greenlights-generic-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/2470510/
9. Deflazacort | C25H31NO6 | CID 189821 - PubChem, accessed September 9, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Deflazacort
10. Deflazacort - brand name list from Drugs.com, accessed September 9, 2025, https://www.drugs.com/ingredient/deflazacort.html
11. Deflazacort (oral route) - Side effects & dosage - Mayo Clinic, accessed September 9, 2025, https://www.mayoclinic.org/drugs-supplements/deflazacort-oral-route/description/drg-20406047
12. Deflazacort - an alternative to prednisolone? - Drug and Therapeutics Bulletin, accessed September 9, 2025, https://dtb.bmj.com/content/37/8/57
13. Deflazacort (Emflaza®) - IBX, accessed September 9, 2025, https://www.ibx.com/pdfs/providers/pharmacy_information/pharmacy_policies/deflazacort.pdf
14. Emflaza (deflazacort) for Duchenne muscular dystrophy, accessed September 9, 2025, https://musculardystrophynews.com/emflaza-deflazacort-duchenne-muscular-dystrophy/
15. Deflazacort Oral Suspension: Package Insert / Prescribing Info - Drugs.com, accessed September 9, 2025, https://www.drugs.com/pro/deflazacort-oral-suspension.html
16. Comparing Deflazacort and Prednisone in ... - Semantic Scholar, accessed September 9, 2025, https://pdfs.semanticscholar.org/3af7/6ed61b8ad481c44ceb2a92e6d9760dd810d9.pdf?skipShowableCheck=true
17. Emflaza: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed September 9, 2025, https://www.drugs.com/emflaza.html
18. HIGHLIGHTS OF PRESCRIBING INFORMATION - accessdata.fda.gov, accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208684s006,208685s007lbl.pdf
19. What Is EMFLAZA® (deflazacort)?, accessed September 9, 2025, https://www.emflaza.com/about-emflaza
20. Efficacy and safety of deflazacort vs prednisone and placebo for ..., accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5109941/
21. MDA Celebrates News of FDA Approval of Emflaza for Treatment of Duchenne Muscular Dystrophy, accessed September 9, 2025, https://www.mda.org/press-releases/mda-celebrates-news-fda-approval-emflaza-treatment-duchenne-muscular-dystrophy
22. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy, accessed September 9, 2025, https://www.mda.org/sites/default/files/2016AANPracticeGuidelineSteroidsDMD.full.pdf
23. Deflazacort - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed September 9, 2025, https://www.pediatriconcall.com/drugs/deflazacort/469
24. DEFLAZACORT VERSUS OTHER GLUCOCORTICOIDS: A COMPARISON - PMC, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2763756/
25. Pharmacotherapy of Duchenne Muscular Dystrophy - PubMed, accessed September 9, 2025, https://pubmed.ncbi.nlm.nih.gov/31375923/
26. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy - PMC, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9398085/
27. Search Orphan Drug Designations and Approvals - FDA, accessed September 9, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=403413
28. Emflaza (deflazacort) FDA Approval History - Drugs.com, accessed September 9, 2025, https://www.drugs.com/history/emflaza.html
29. EMA recommends approval of first ever treatment for all DMD patients | Duchenne UK, accessed September 9, 2025, https://www.duchenneuk.org/first-ever-treatment-for-all-dmd-patients-recommended-for-approval-by-the-ema/
30. HIGHLIGHTS OF PRESCRIBING INFORMATION - accessdata.fda.gov, accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208684s005,208685s005lbl.pdf
31. Emflaza (deflazacort) dosing, indications, interactions, adverse effects, and more, accessed September 9, 2025, https://reference.medscape.com/drug/emflaza-deflazacort-1000120
32. Steroids - Parent Project Muscular Dystrophy, accessed September 9, 2025, https://www.parentprojectmd.org/care/care-guidelines/by-area/steroids/
33. Deflazacort Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 9, 2025, https://www.drugs.com/dosage/deflazacort.html
34. Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial - PubMed, accessed September 9, 2025, https://pubmed.ncbi.nlm.nih.gov/35500465/
35. Dosing & How to Take EMFLAZA® (deflazacort), accessed September 9, 2025, https://www.emflaza.com/dosing
36. Deflazacort: MedlinePlus Drug Information, accessed September 9, 2025, https://medlineplus.gov/druginfo/meds/a617024.html
37. Deflazacort Tablets (Emflaza): Uses & Side Effects - Cleveland Clinic, accessed September 9, 2025, https://my.clevelandclinic.org/health/drugs/20103-deflazacort-tablets
38. Dosing & Administration - EMFLAZA® (deflazacort), accessed September 9, 2025, https://hcp.emflaza.com/dosing-administration
39. EMFLAZA® (deflazacort): DMD Treatment for Kids 2 Years & Older, accessed September 9, 2025, https://www.emflaza.com/
40. Reference ID: 4053971 This label may not be the latest approved by FDA. For current labeling information, please visit https:// - accessdata.fda.gov, accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
41. Deflazacort: Package Insert / Prescribing Information - Drugs.com, accessed September 9, 2025, https://www.drugs.com/pro/deflazacort.html
42. Important Safety Information - EMFLAZA® (deflazacort), accessed September 9, 2025, https://hcp.emflaza.com/important-safety-information
43. Emflaza (deflazacort): Uses, Side Effects, Dosage & Reviews - GoodRx, accessed September 9, 2025, https://www.goodrx.com/emflaza/what-is
44. Tolerability: Safety Profile | EMFLAZA® (deflazacort), accessed September 9, 2025, https://hcp.emflaza.com/tolerability/safety-profile
45. Calcort 6mg Tablets Deflazacort Important things you need to know about Calcort, accessed September 9, 2025, https://www.medicines.org.uk/emc/files/pil.13999.pdf
46. Deflazacort and Alcohol/Food Interactions - Drugs.com, accessed September 9, 2025, https://www.drugs.com/food-interactions/deflazacort.html
47. Deflazacort Interactions Checker - Drugs.com, accessed September 9, 2025, https://www.drugs.com/drug-interactions/deflazacort.html
48. pmc.ncbi.nlm.nih.gov, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2763756/#:~:text=Clinical%20studies%20have%20indicated%20that,%3A1.2%20to%201%3A1.5.
49. Deflazacort vs. Prednisone: 5 Differences Between These Muscular Dystrophy Treatments, accessed September 9, 2025, https://www.goodrx.com/conditions/muscular-dystrophy/deflazacort-vs-prednisone
50. Deflazacort in rheumatoid arthritis: A scoping review | Revista Colombiana de Reumatología (English Edition) - Elsevier, accessed September 9, 2025, https://www.elsevier.es/en-revista-revista-colombiana-reumatologia-english-edition--474-articulo-deflazacort-in-rheumatoid-arthritis-a-S2444440524000244
51. Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent, accessed September 9, 2025, https://ctap-duchenne.org/wp-content/uploads/2020/01/MUS-61-26.pdf
52. Associations Between Deflazacort Versus Prednisone/Prednisolone and Markers of Disease Progression in Clinically Important Subgroups of Patients with Duchenne Muscular Dystrophy (P1-1.Virtual) - Neurology.org, accessed September 9, 2025, https://www.neurology.org/doi/10.1212/WNL.98.18_supplement.1437
53. Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology - PMC - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4773944/